Advertisement

Topics

FDA Expands Approval of Epculsa for the Treatment of Hepatitis C in Patients Co-Infected with HIV

09:37 EDT 2 Aug 2017 | Speciality Pharma Journal

FOSTER CITY, Calif.–(BUSINESS WIRE)–Gilead Sciences, Inc. (NASDAQ: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved updated labeling for Epclusa® (sofosbuvir 400mg/velpatasvir 100mg), the first all-oral, pan-genotypic, once-daily single tablet regimen (STR) for the treatment of adults with chronic hepatitis C virus (HCV) infection, to include use in patients co-infected with HIV. …

Original Article: FDA Expands Approval of Epculsa for the Treatment of Hepatitis C in Patients Co-Infected with HIV

NEXT ARTICLE

More From BioPortfolio on "FDA Expands Approval of Epculsa for the Treatment of Hepatitis C in Patients Co-Infected with HIV"

Quick Search
Advertisement
 

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Gastroenterology
Astroesophageal Reflux Disease (GERD) Barrett's Esophagus Celiac Disease Cholesterol Crohn's Disease Gastroenterology Hepatitis Hepatology Irritable Bowel Syndrome (IBS) Pancreatitis Peptic Ulcer Disease...